Big Changes Are Coming in Hepatitis C
- Fred PoordadAffiliated withCedars-Sinai Medical Center Email author
The story of hepatitis C virus (HCV) therapy is about to add one of its biggest chapters. From the serendipitous beginnings in the 1980s when investigators noted that interferon improves liver enzymes in non-A, non-B hepatitis, to the discovery and naming of the hepatitis virus, to the addition of ribavirin, to the pegylation of interferon, and now to the first direct-acting antivirals (DAA), the history of HCV is an intriguing one that continues to unfold. Along with the first DAAs, other important findings have helped explain long-observed differences between various ethnic groups, as well as new predictive information that can be gleaned from some of the observed adverse events.
KeywordsHepatitis C Pegylated interferon Ribavirin Direct-acting antivirals Telaprevir Boceprevir Protease inhibitors Polymerase inhibitors
- Big Changes Are Coming in Hepatitis C
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Current Gastroenterology Reports
Volume 13, Issue 1 , pp 72-77
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Hepatitis C
- Pegylated interferon
- Direct-acting antivirals
- Protease inhibitors
- Polymerase inhibitors
- Industry Sectors
- Fred Poordad (1)
- Author Affiliations
- 1. Cedars-Sinai Medical Center, 8635 West Third Street, Suite 1060, Los Angeles, CA, 90048, USA